Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

Autor: Richard D. Gelber, Xin V. Wang, Bernard F. Cole, David Cameron, Fatima Cardoso, Vivianne Tjan-Heijnen, Ian Krop, Sherene Loi, Roberto Salgado, Astrid Kiermaier, Elizabeth Frank, Debora Fumagalli, Carmela Caballero, Evandro de Azambuja, Marion Procter, Emma Clark, Eleonora Restuccia, Sarah Heeson, Jose Bines, Sibylle Loibl, Martine Piccart-Gebhart

Publikováno v: European Journal of Cancer, 166, 219-228. ELSEVIER SCI LTD
2022, ' Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial ', European Journal of Cancer, vol. 166, pp. 219-228 . https://doi.org/10.1016/j.ejca.2022.01.031

AIM: The APHINITY trial showed that adding adjuvant pertuzumab (P) to trastuzumab and chemotherapy, compared with adding placebo (Pla), significantly improved invasive disease-free survival (IDFS) for patients with HER2+ early breast cancer both over

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39ea7784312d3198e47cc5b66a1e3df0
https://doi.org/10.1016/j.ejca.2022.01.031

Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer

Autor: Tsang Wu Liu, Mihaela Sicoe, Giuseppe Viale, Hans-Joachim Lueck, Christoph Thomssen, Nicolas Wilcken, Michael S. Ewer, Evandro de Azambuja, Ian E. Krop, Estefania Monturus, Ling-Ming Tseng, Young-Hyuck Im, Debora Fumagalli, Marion Procter, Eleonora Restuccia, Hervé Bonnefoi, Tadeusz Pienkowski, Emma Clark, Marco Colleoni, Guy Jerusalem, Martine Piccart, Martin Andersson, Susan Dent, Linda Reaby, José Bines, Sébastien Guillaume, Richard D. Gelber, Masakazu Toi

Publikováno v: Cancer Research. 80:GS1-04

Background: The APHINITY trial demonstrated that pertuzumab, when added to adjuvant trastuzumab and chemotherapy, modestly but statistically significantly improved invasive disease-free survival (IDFS) among patients with HER2-positive, operable brea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b13a4c10e30341ce2a2035ef3518050e
https://doi.org/10.1158/1538-7445.sabcs19-gs1-04

Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial

Autor: Maria Alice Franzoi, Marion Procter, Chris Twelves, Noam Pondé, Daniel Eiger, Orianne Emond, Emma Clark, Damien Parlier, Sébastien Guillaume, Linda Reaby, Evandro de Azambuja, Jose Bines

Publikováno v: Ecancermedicalscience. 16

Geographic location and national income may influence access to innovation in healthcare. We aimed to study if geographical location and national income influenced the timelines to activate the global phase III APHINITY trial, evaluating adjuvant per

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::293e7a23b04144f96f1c003c4be6edab
https://pubmed.ncbi.nlm.nih.gov/35702414

Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer

Autor: Christian Jackisch, Amal Arahmani, Jennifer A. Petersen, Emma Clark, José Baselga, Martine Piccart, Elizabeth S. Frank, Giuseppe Viale, Amir Sonnenblick, Marion Procter, Eleonora Restuccia, Linda Reaby, José Bines, Damien Parlier, Debora Fumagalli, Richard D. Gelber, Claire Barton

Publikováno v: Br J Cancer

Background We assessed health-related quality of life (symptoms of therapy/patient functioning/global health status), in APHINITY (pertuzumab/placebo, trastuzumab, and chemotherapy as adjuvant HER2-positive early breast cancer therapy). Methods Patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b693638ee9772c365ab475e3e80af63
https://pubmed.ncbi.nlm.nih.gov/33828257

Abstract P1-13-07: Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in HER2-Positive breast cancer

Autor: R. D. Gelber, Emma Clark, Thomas M. Suter, Amal Arahmani, E. de Azambuja, Dimitrios Zardavas, J. Baselga, Marion Procter, Eleonora Restuccia, José Bines, Jennifer Eng-Wong, M.J. Piccart, V Van Dooren, G. Viale, G. von Minckwitz

Publikováno v: Cancer Research. 78:P1-13

Background Diarrhea is the most commonly reported adverse event (AE) on pertuzumab (Ptz) in both early and metastatic breast cancer (BC) settings. We report safety analyses of diarrhea from the large adjuvant APHINTY study in HER2 positive early brea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4ac8e83679c8e498f4eb2f15b10f72de
https://doi.org/10.1158/1538-7445.sabcs17-p1-13-07